<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546310</url>
  </required_header>
  <id_info>
    <org_study_id>9936-103</org_study_id>
    <nct_id>NCT02546310</nct_id>
  </id_info>
  <brief_title>Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>P1vital Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if treatment with HTL0009936 will lead to changes in neural activity, measured
      using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and
      working memory, learning and executive functioning.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood oxygen level dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BOLD signal in fMRI in other brain regions involved in the regulation of cognitive processes during cognitive tasks</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral blood flow, assessed using Arterial Spin Labelling (ASL)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>event related potentials</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>HTL0009936 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL0009936 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL0009936 matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0009936</intervention_name>
    <arm_group_label>HTL0009936 high dose</arm_group_label>
    <arm_group_label>HTL0009936 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0009936 matching placebo</intervention_name>
    <arm_group_label>HTL0009936 matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy on the basis of medical history, physical examination, vital signs, 12-lead
             ECG, haematology, blood chemistry, urinalysis and a pre-study psychological
             assessment.

          -  Mini Mental State Examination (MMSE) Score of â‰¥24.

          -  Intermediate or extensive metaboliser as determined by CYP2D6 genotype.

          -  Fluent English speaker.

          -  Right-handed.

          -  Not a regular smoker

        Exclusion Criteria:

          -  Recreational drug use within 3 months prior to Screening Visit.

          -  Positive alcohol breath test.

          -  Positive urine drug screen.

          -  Consumption of large amounts of caffeinated drinks.

          -  Consumption of any food or any drinks containing cranberry, pomegranate, star fruit,
             grapefruit, pomelos, exotic citrus fruits or Seville oranges.

          -  Ultra-rapid or poor metabolizer as determined by CYP2D6 genotype.

          -  By self-report, taking two or more daytime naps per week which in the opinion of the
             investigator is likely to interfere with the ability of the subject to complete the
             study procedures.

          -  History of, or presents (in the opinion of the Investigator) with, significant
             neurological or psychiatric conditions.

          -  Personal or family history of congenital long QT syndrome or sudden death.

          -  Concomitant use of drugs that are metabolised by and/or are inhibitors of CYP2D6.

          -  Concomitant use of drugs that are substrates for the organic cation transporter 2.

          -  History of significant claustrophobia.

          -  Fulfils any of the MRI contraindications on the standard site radiography screening
             questionnaire (e.g. history of surgery involving metal implants).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neuroscience and Psychiatry Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

